Making science matter: A vision for a new century of life-changing science: Peter Schultz, PhD
Making science matter: A vision for a new century of life-changing science: Peter Schultz, PhD

January 10, 2024

In the inaugural lecture of the 2024 Centennial Front Row series, President and CEO Peter Schultz will illuminate how Scripps Research is building on its storied past—a remarkable century of discovery and innovation—to establish a new paradigm for the future of science and medicine. Under Schultz’s leadership, Scripps Research is expanding its global impact by empowering exceptional scientists to pursue groundbreaking ideas and seamlessly blending curiosity-fueled science with impact-driven drug discovery. Schultz shared how this unique approach is already giving rise to a new generation of first-in-class medicines against cancers, heart disease, deadly pathogens, neurological disorders, and many other health threats.

View Presentation


How experiences shape the developing brain and impact neurological diseases: Hollis Cline, PhD
How experiences shape the developing brain and impact neurological diseases: Hollis Cline, PhD

February 21, 2024

As we age, learn and grow over our lifetimes, the brain continually responds and adapts to what we experience. In this Front Row lecture, Scripps Research Chair of the Department of Neuroscience Hollis Cline revealed how sensory experiences shape the brain during development and aging—particularly visual experiences. Cline’s work has been critical in revealing how key visual brain circuits become disrupted in neurodevelopmental disorders, as well as in mapping the different communication pathways between neurons.

View Presentation


Bringing precision therapy to mental disorders: Hugh Rosen, MD, PhD
Bringing precision therapy to mental disorders: Hugh Rosen, MD, PhD

March 20, 2024

Mental disorders like depression and schizophrenia affect the lives of millions of people around the world, and yet, available treatment options have remained the same for decades. In this free Front Row lecture, Scripps Research professor Hugh Rosen shared how his pioneering research led to the development of the drug navacaprant, which precisely targets one of the brain’s behavioral circuits and is currently in clinical testing for major depressive disorder. Harnessing his expertise as a physician-scientist, Rosen has discovered and developed multiple other medicines, including ozanimod—a breakthrough treatment approved for multiple sclerosis and ulcerative colitis.

View Presentation


Fixing the misfolded proteins that cause dementia and heart failure: Jeffery Kelly, PhD
Fixing the misfolded proteins that cause dementia and heart failure: Jeffery Kelly, PhD

May 15, 2024

All proteins have a correct way of “folding” themselves into their three-dimensional structures. When this folding process goes awry, including processes leading to protein misassembly, a number of devastating diseases can result. In this free Front Row lecture, Scripps Research professor Jeffery Kelly shared how he is developing novel therapeutic strategies to target these protein misfolding diseases, which lead to deterioration of the heart and brain. His multi-disciplinary research has already led to the development of an FDA-approved drug available in the pharmacy called tafamidis (Vyndaqel® and Vyndamax®): a medicine that slows the progression of the neurodegenerative disease familial amyloid polyneuropathy and the degenerative heart disease called TTR cardiomyopathy.

View Presentation